

ASX RELEASE
21 August 2009

Successful MoxDuo ™IR trial results are the key accomplishment for the financial year ended 30 June 2009

Sydney, Australia & Bedminster, NJ – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced during the financial year ended 30 June 2009 the successful completion of a Phase 3 program pilot study comparing the efficacy and safety profile of MoxDuo™ IR against component doses of morphine and oxycodone. Results demonstrated that MoxDuo™ IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo™ IR produced fewer and less intense side effects. These clinical results are the highlight of a successful year for the Company.

"During the financial year ended 30 June 2009 we significantly advanced our comprehensive Phase 3 clinical trial program and clearly demonstrated the clinical and commercial value of our patented Dual-Opioid™, with the potential to give patients greater tolerability than morphine or oxycodone alone." said Dr. John Holaday, QRxPharma's Managing Director and CEO. "Additional studies evaluating MoxDuo™ IR versus Percocet® in patients with knee replacement surgery were completed in early July 2009, and analysis of the data is underway" he added.

Summary of key highlights for the financial year ended 30 June 2009 were:

Enhancement of the potential market opportunity of MoxDuo™ IR:

- Completion of a 197 patient Phase 3 programme comparator study where the patient data demonstrated that MoxDuo™ IR reduces pain significantly more than its component doses; further, when compared to equianalgesic doses of morphine and oxycodone, MoxDuo™ IR produced fewer and less intense side effects.

- Initiation of a second Phase 3 program pilot comparator study to evaluate the analgesic efficacy and safety profile of MoxDuo™ IR capsules in 44 patients with the dosing of patients completed in early July 2009.

- Lodgement of "combination rule" Phase 3 study protocol for MoxDuo™ IR with submission in June 2009 to US Food and Drug Administration for Special Protocol Assessment approval.

Expansion of product portfolio with Second MoxDuo™ product entering the clinic:

- Phase 2 comparative proof-of-concept study of MoxDuo™ IV (intravenous morphine and oxycodone) was initiated with the first patient dosed in July 2009.

Developmental progress on Dual Opioid™product with largest market potential:

- MoxDuo™ CR, a continuous release formulation of QRxPharma's Dual-Opioid™ designed to provide 12 hours of pain relief in patients with moderate to severe pain, continues on track to initiate Phase 1 studies by the end of 2009.

Financial results released today reported the Company retaining $17.8 million in cash reserves at 30 June 2009. The net loss for the year ended 30 June 2009 of $13.5 million (2008: net loss $36.6 million) was in line with expectations of the Board of Directors, and resulted from the fulfilling of research and development activities in the progression of the Company's clincial pipeline candidates and preclinical stage drugs. The results were favourably impacted by foreign exchange gains of $5.3 million (2008: $2.6 million loss) arising from holding cash reserves primarily in US dollars. In addition, the prior year loss carried an impairment charge relating to "Torsin" intellectual property of $14.6 million (2009: $nil).

The Company's patented Dual Opioid™ products target moderate to severe acute and chronic pain, a US$10 billion global market. QRxPharma remains on track to launch its first dual opioid product, MoxDuo™ IR, in 2011.

###

For more information please contact:
John Holaday
Managing Director and Chief Executive Officer
Tel: +1 301 908 3086
Email: john.holaday@qrxpharma.com

Chris J Campbell
Chief Financial Officer and Company Secretary
Tel: +61 2 9492 8021
Email: chris.campbell@qrxpharma.com

Alicia Moran, PR Contact
Tel: +1 703 739 2424 (x110)
Email: alicia@brightlinemedia.com

Forward Looking Statements

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events.

By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialise its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuo™ IR, the first combination opioid product for the improved control of moderate to severe pain, successfully completed a Phase 3 study and a pilot Combination Rule study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information: www.QRxPharma.com.